CClinicalTrials.gg
Sign In
CompletedNCT00273390Updated Jul 4, 2011

A Clinical Trial of Infliximab for Uveitis

An interventional study of Remicade (infliximab) in Uveitis, sponsored by Oregon Health and Science University. Completed. Open to participants aged 9 Years and older. Per ClinicalTrials.gov, last updated 2011-07-04.

Sponsored by Oregon Health and Science University · Not applicable and Interventional

Phase
Not applicable
Study type
Interventional
Enrollment
32
Ages
9 Years and older
Sex
All
01

Study summary

This project is designed to test the hypothesis that inhibition of binding between tumor necrosis factor alpha (TNF-alpha) and its receptors using Remicade (infliximab, chimeric mouse/human IgG1K monoclonal antibody directed against human TNF-alpha, Centocor, Malvern,PA) is clinically useful for patients with uveitis that is refractory to other forms of systemic immunosuppressive therapy.

02

Conditions studied

  • Uveitis

Browse trials for

03

In context

Uveitis

335 studies on the registry are indexed under Uveitis; 37 are open to participants now.

This study's enrollment of 32 is close to the median of 30 across 208 interventional studies indexed under Uveitis.

Browse Uveitis studies →

Lead sponsor

Oregon Health and Science University is the lead sponsor of 676 studies on the registry; 136 are open to participants now.

Of its 49 completed or terminated interventional studies of FDA-regulated products, 36 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
9 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. The study group will include patients suffering from treatment-resistant vision-threatening uveitis who attend the Uveitis Clinic at Casey Eye Institute.
  2. We plan to enroll 32 patients.

Exclusion criteria

Exclusion Criteria:

  1. Patients with ocular or systemic infection.
  2. Patients with the subtype of uveitis termed pars planitis who have MRI scan evidence of demyelination. There is a theoretical risk of adverse outcome of TNF-alpha inhibition on the clinical course of multiple sclerosis. Patients who suffer from pars planitis are at increased risk of developing multiple sclerosis.
  3. Children under the age of 9.
  4. Patients with known sensitivity to mouse proteins. Remicade is a chimeric protein with human and murine components.
  5. Patients with history of cancer (exception- skin cancers which are curatively resected), organ transplantation (exception- cornea), recent drug or alcohol addiction, or inability to keep appointments.
  6. Patients with other serious systemic diseases that could interfere with participation in the study.
  7. It is specifically noted that pregnant women and nursing mothers will be excluded from this study.
05

Study design

Phase
Not applicable
Enrollment
32 participants

Interventions

  • DrugRemicade (infliximab)
06

Study locations

No study locations are listed for this record.

07

References and documents

Publications

  • Suhler EB, Smith JR, Wertheim MS, Lauer AK, Kurz DE, Pickard TD, Rosenbaum JT. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol. 2005 Jul;123(7):903-12. doi: 10.1001/archopht.123.7.903. PubMed 16009830 ↗
  • Suhler EB, Smith JR, Giles TR, Lauer AK, Wertheim MS, Kurz DE, Kurz PA, Lim L, Mackensen F, Pickard TD, Rosenbaum JT. Infliximab therapy for refractory uveitis: 2-year results of a prospective trial. Arch Ophthalmol. 2009 Jun;127(6):819-22. doi: 10.1001/archophthalmol.2009.141. No abstract available. PubMed 19506209 ↗
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 4, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00273390
Lead sponsor
Oregon Health and Science University
Collaborators
Centocor, Inc.
First posted
Jan 9, 2006
Start date
Aug 2001
Primary completion
Dec 2006
Completion
Dec 2006
Last update
Jul 4, 2011

Study contacts

James T Rosenbaum, MD
principal investigator · Oregon Health and Science University
Eric B Suhler, MD
study director · Oregon Health and Science University
Justine Smith, MBBS, Phd
study director · Oregon Health and Science University
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Uveitis→

Other studies from this sponsor

Oregon Health and Science University

Start the discussion